Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11127-32. doi: 10.1073/pnas.1410432111. Epub 2014 Jul 14.

Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Author information

1
Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA 95616;Department of Food Science, University of Massachusetts-Amherst, Amherst, MA 01003;
2
Center for Vascular Biology Research andDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115;
3
Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA 95616;
4
Department of Biomedical Engineering, and.
5
Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616;
6
Division of Pediatric Oncology, Dana-Farber Cancer Institute, andDepartment of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115; and.
7
Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616;US Department of Veterans Affairs Medical Center, Sacramento, CA 95655.
8
Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA 95616; bdhammock@ucdavis.edu.

Abstract

Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis. COX-2 inhibitors, which block the formation of prostaglandins, suppress tumor growth, whereas sEH inhibitors, which increase endogenous EETs, stimulate primary tumor growth and metastasis. However, the functional interactions of these two pathways in cancer are unknown. Using pharmacological inhibitors as probes, we show here that dual inhibition of COX-2 and sEH synergistically inhibits primary tumor growth and metastasis by suppressing tumor angiogenesis. COX-2/sEH dual pharmacological inhibitors also potently suppress primary tumor growth and metastasis by inhibiting tumor angiogenesis via selective inhibition of endothelial cell proliferation. These results demonstrate a critical interaction of these two lipid metabolism pathways on tumorigenesis and suggest dual inhibition of COX-2 and sEH as a potential therapeutic strategy for cancer therapy.

PMID:
25024195
PMCID:
PMC4121808
DOI:
10.1073/pnas.1410432111
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center